Retinal Physician

In-depth coverage of the latest advances in retinal diseases as well as surgical intervention in posterior segment care.

[Retinal Physician @RetinalPhys]

🔬 What's happening in retina clinical research?

Explore Retinal Physician's November 2026 Clinical Trial Update, featuring studies in AMD, DME, RVO, and uveitis.

👁️ View the latest listings: https://t.co/NDEfDVan3d

[Retinal Physician @RetinalPhys]

🚨 Medicare is cutting ASC facility payments for vitrectomy by 2% in 2027.

Retina leaders warn of potential consequences for surgical access.

👁️ Get the details: https://t.co/3iKa0o7Rmn
#MedicareCuts #Vitrectomy

[Retinal Physician @RetinalPhys]

👓 Could AI-powered smart glasses transform everyday life for people with visual impairments?

Eyedaptic has introduced Eva, a new AI assistant for its EYE7 smart glasses, designed to make everyday activities easier and more accessible.

🤖 Learn more: https://t.co/Jcvude9xof

[Retinal Physician @RetinalPhys]

🌎📍 Greetings from the end of the world!

Retinal Physician has touched down in Ushuaia, Argentina, for the 22nd Annual Meeting #SARyV2026!

We're excited to bring you the latest insights, news, and expert interviews from the event - stay tuned!
#RetinalPhysician

[Retinal Physician @RetinalPhys]

📖 The November–December issue of Retinal Physician is here!

Explore wet AMD trials, independent practice, AI in clinical research, retina OR challenges, and more.

👁️ Read the latest issue: https://t.co/Dmew4m9pDr

#RetinalPhysician #Retina

[Retinal Physician @RetinalPhys]

🌎 Retina at the End of the World!

Next week, Retinal Physician heads to Ushuaia, Argentina, for the XXII International Congress of the Argentine Society of Retina and Vitreous!

🎥 Watch the video invitation: https://t.co/Dehm89Q5bI

#Retina

[Retinal Physician @RetinalPhys]

🧬 Nacuity has dosed its first patient in a phase 3 trial of NPI-001 for Usher-associated retinitis pigmentosa.

The 24-month study will evaluate whether the treatment can slow disease progression in up to 80 adults.

🔗 Read more: https://t.co/R7DstMVVw3

#Retina

[Retinal Physician @RetinalPhys]

👁️ Could gene therapy reduce wet AMD injections?

Two-year PRISM data show 66% of more recently diagnosed patients needed no supplemental injections after investigational 4D-150.

🎥 Veeral Sheth, MD, discusses the findings.

▶️ https://t.co/Dwhi70NdAY

#AAO2026 #Retina

[Retinal Physician @RetinalPhys]

👁️ Does JIA-associated uveitis really end with childhood?

For many patients, inflammation, treatment dependence and ocular complications can continue into adulthood.

What should ophthalmologists know?

🔗 Read more: https://t.co/t9vyAuvu8j

#Uveitis #Retina

[Retinal Physician @RetinalPhys]

👁️ Could gene therapy reduce the burden of DME injections?

At #AAO2026, Arshad M. Khanani, MD, discusses promising early Phase 2 ELAAVATE findings with Diana V. Do, MD.

🎥 Watch: https://t.co/yhiqh8BpcU

#Retina #GeneTherapy

[Retinal Physician @RetinalPhys]

EyePoint announced plans to reduce its workforce by 53% and end its phase 3 nAMD trials early after Duravyu failed to meet the primary endpoint in the LUCIA trial. The company will shift its focus to ongoing phase 3 studies in DME. Read here: https://t.co/z8wYRNeofk

[Retinal Physician @RetinalPhys]

👁️ Can a single injection deliver lasting benefits in diabetic retinopathy?

At #RetinaSociety2026, Nikolas London, MD, reviews 3-year ALTITUDE findings for investigational gene therapy sura-vec.

🎥 Watch: https://t.co/souUEJr07n

[Retinal Physician @RetinalPhys]

👁️ New Phase 3 VISTA results for investigational XLRP gene therapy laru-zova debuted at #AAO2026.

🎥 Robert A. Sisk, MD, discusses visual acuity findings, safety and next steps in an exclusive Retina Minute interview.

▶️ https://t.co/G2m6zXOx8A

#Retina #GeneTherapy

[Retinal Physician @RetinalPhys]

👁️ LUGANO: 42% less treatment burden, but a missed primary endpoint.

At #RetinaSociety2026, Charles C. Wykoff, MD, PhD, and Carl Regillo, MD, FACS, discuss the phase 3 EYP-1901 findings in wet AMD.

🎥 Watch: https://t.co/3UrdThYKLn

#Retina #WetAMD

[Retinal Physician @RetinalPhys]

📍 Coverage from #RetinaSociety2026

👁️ Could epiretinal membrane removal reduce injection burden in wet AMD?

In a small study, two-thirds of patients stopped or reduced anti-VEGF injections following surgery.

🔗 Read more: https://t.co/uthCP4q5X9
#Retina

[Retinal Physician @RetinalPhys]

👁️ Stay current on the latest developments shaping retinal care.

Subscribe to Retinal Physician for coverage of clinical trials, treatments, surgical techniques, and more.
📩 Sign up: https://t.co/G0RdewX3V0
#Ophthalmology #Retina

[Retinal Physician @RetinalPhys]

🔬 At #AAO2026, Charles C. Wykoff, MD, PhD, presented positive phase 3 DAYBREAK results for investigational nAMD therapies tarcocimab and tabirafusp.

54% of tarcocimab patients achieved 24-week dosing intervals.

🔗 Read more:https://t.co/Z9G5z20yWi

#Retina #WetAMD

[Retinal Physician @RetinalPhys]

📍 We're in New Orleans! ⚜️

AAO 2026 is officially underway, and the Retinal Physician team is here for Retina Subspecialty Day! 👁️

We're excited to reconnect with the retina community, explore the latest developments in retinal care, and catch up with familiar faces!

#AAO2026

[Retinal Physician @RetinalPhys]

👁️ Could optogenetics offer new hope for severe vision loss?

Diana V. Do, MD, and Allen C. Ho, MD, discuss the FDA's acceptance of MCO-010's application, how the therapy works and what's next.

🎥 Watch: https://t.co/CaN5u38rqa

#Retina #Optogenetics

[Retinal Physician @RetinalPhys]

�� When are eye drops no longer enough for noninfectious uveitis?

Howard F. Fine, MD, explores when to escalate treatment and how injectable corticosteroids can help provide targeted, durable control.

💡 Read more: https://t.co/Isethniyd7

#Uveitis #Retina